COVID Treatments: Gilead Stock Doesn’t Reflect Optimism About Remdesivir
- Friday, May 8, 2020, 7:10
- Market
- Add a comment
Last Friday, Gilead received U.S. FDA authorization for emergency use of its wide-spectrum anti-viral drug Remdesivir for severe cases of COVID-19 after the drug showed some effectiveness in reducing recovery times. Separately, Japan has also approved the drug for the treatment of COVID-19…
About the Author
admin123 has written 23527 stories on this site.
